Nuvation Bio (NUVB)

• Market cap: $1.83B
• 1 day: 0.75%
• 5 days: -9.8%
• 1 month: -41.06%
• 3 months: 1.52%
• 6 months: 117.07%
• Year to date: -37.76%
• 1 year: 120.66%
• 5 years: -47.9%
• 10 years: -44.95%
• Sector: Healthcare
• Industry: Biotechnology

About: Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Employees: 291